Edoxaban: Defining place in therapy for the newest direct acting oral anticoagulant
Edoxaban is the most recently approved factor Xa inhibitor within the class of direct oral anticoagulants (DOACs). Like other DOACs, edoxaban was approved by the FDA for treatment of venous thromboembolism and prevention of stroke in patients with non-valvular atrial fibrillation. Similar to other DOACs, edoxaban has fewer drug-drug interactions than warfarin and does not require routine laboratory monitoring. Unlike other DOACs, edoxaban has yet to be approved for secondary or postoperative venous thromboembolism thromboprophylaxis.
Source: The American Journal of Medicine - Category: Journals (General) Authors: Caitlin M. Gibson, Shannon W. Finks Tags: Review Source Type: research
More News: Atrial Fibrillation | Coumadin | General Medicine | Laboratory Medicine | Stroke | Thrombosis | Warfarin